USE OF NKp46 FOR PREVENTING DIABETES

Ofer Mandelboim; Angel Porgador; Yaakov Naparstek; Chamutal Gur

USE OF NKp46 FOR PREVENTING DIABETES

Ofer Mandelboim (Inventor), Angel Porgador (Inventor), Yaakov Naparstek (Inventor), Chamutal Gur (Inventor)

The Shraga Segal Department of Microbiology, Immunology and Genetics

Research output: Patent

Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Original language	English
Patent number	WO2010106542
IPC	A61K 38/ 17 A I
Priority date	9/11/09
State	Published - 23 Sep 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{f772e9ae44504f5f9a31e7fd90a06897,

title = "USE OF NKp46 FOR PREVENTING DIABETES",

abstract = "The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.",

author = "Ofer Mandelboim and Angel Porgador and Yaakov Naparstek and Chamutal Gur",

year = "2010",

month = sep,

day = "23",

language = "English",

type = "Patent",

note = "WO2010106542; A61K 38/ 17 A I",

}

TY - PAT

T1 - USE OF NKp46 FOR PREVENTING DIABETES

AU - Mandelboim, Ofer

AU - Porgador, Angel

AU - Naparstek, Yaakov

AU - Gur, Chamutal

PY - 2010/9/23

Y1 - 2010/9/23

N2 - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

AB - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

M3 - Patent

M1 - WO2010106542

ER -

USE OF NKp46 FOR PREVENTING DIABETES

Abstract

UN SDGs

Fingerprint

Cite this